Market Overview

A Peek Into The Market Before The Trading Starts

Related TXT
Defense Stock Roundup: Textron Reports Impressive Q2 Earnings, Lockheed Wins Indian Super Hercules Contract
Morgan Stanley Sees 2Q14 Beat Raises Chances Of FY14 Guidance Beat For Textron
Related CUI
CUI Global (CUI) Falls: Stock Goes Down 6.4% - Tale of the Tape
Zacks Rank #5 Additions for Wednesday - Tale of the Tape

Pre-open movers US stock futures are lower this morning, after a strong decline in global stock markets. Futures for the Dow Jones Industrial Average tumbled 140 points to 12,633.00 and S&P 500 index futures fell 14 points to 1,344.20. Nasdaq 100 futures dropped 30.75 points to 2,582.50.

A Peek Into Global Markets European markets were lower today. The STOXX Europe 600 Index declined 1.93%, French CAC 40 index fell 2.05%. London's FTSE 100 Index moved down 1.67% and German DAX 30 index dropped 1.60%.

Asian markets ended lower, with Japan's Nikkei Stock Average dropping 1.86%, China's Shanghai Composite falling 1.26% and Australia's S&P/ASX 200 moving down 1.69%. Hong Kong's Hang Seng index dropped 2.99% and India's Sensex fell 1.64%.

Broker Recommendation Analysts at RBC Capital downgraded Textron (NYSE: TXT) from “outperform” to “sector perform.” The target price for Textron has been lowered from $32 to $28.

Textron shares fell 0.72% to close at $26.31 on Friday.

Breaking news

  • CUI Global (NASDAQ: CUI) today announced it has signed a non-exclusive agreement with Energy Measurement Consulting LLC (EMC) out of Houston, Texas for North American Sales of its Vergence™ GasPT2 natural gas metering device. To read the full news, click here.
  • Illumina (NASDAQ: ILMN) today announced that the company has sought leave to file counterclaims against Intelligent Bio-Systems, Inc. (IBS) and Qiagen NV, which recently acquired IBS, in response to the patent lawsuit brought by Columbia University and IBS on March 26, 2012 in U.S. District Court in Wilmington, Delaware. To read the full news, click here.
  • Pluristem Therapeutics (NASDAQ: PSTI) today announced it is preparing to apply to the U.S. Food and Drug Administration for approval of its PLacental eXpanded (PLX) cells for the treatment of aplastic bone marrow as an Orphan Drug. To read the full news, click here.
  • ReneSola Ltd (NYSE: SOL) today announced that it has sold 5.95 MW of its high-quality, high-efficiency Virtus modules to Solargain PV Pty Ltd, one of the top solar distributors in Australia and one of Australia's largest integrated solar energy and solar hot water suppliers. To read the full news, click here.

Posted-In: RBC Capital US Stock FuturesNews Futures Global Pre-Market Outlook Markets

 

Related Articles (ILMN + CUI)

Around the Web, We're Loving...

Partner Network

Get Benzinga's Newsletters

Benzinga Professional